Amazing how blastoids are bridging the gap between basic research and clinical applications for implantation failure. The patient-specific variability thing is key, dunno why more people aren't talking about how wildly different the drug responses were across patients. That Beijing study combining endometrial organoids with blastoids to screen FDA compunds is basically precision medicine before it even reaches the clinic. Karvas's 3D gel approach solving the disorganization probem was slick too.
Agree, it’s amazing how this technology can provide platforms to test and develop new therapies, not only for implantation failure, blastoids can also have a great impact on organogenesis, precision medicine, etc. the possibilities are incredibly broad. Looking ahead, there will be a growing need to test therapies across diverse populations to avoid bias. This is just the beginning, and it’s exciting to see how quickly the gap is being bridged
Amazing how blastoids are bridging the gap between basic research and clinical applications for implantation failure. The patient-specific variability thing is key, dunno why more people aren't talking about how wildly different the drug responses were across patients. That Beijing study combining endometrial organoids with blastoids to screen FDA compunds is basically precision medicine before it even reaches the clinic. Karvas's 3D gel approach solving the disorganization probem was slick too.
Agree, it’s amazing how this technology can provide platforms to test and develop new therapies, not only for implantation failure, blastoids can also have a great impact on organogenesis, precision medicine, etc. the possibilities are incredibly broad. Looking ahead, there will be a growing need to test therapies across diverse populations to avoid bias. This is just the beginning, and it’s exciting to see how quickly the gap is being bridged